Jylamvo: Uses, Dosage & Side Effects
Methotrexate oral solution for the treatment of rheumatoid arthritis, severe psoriasis, and certain cancers in adults and children
Jylamvo is a brand name for methotrexate in oral solution form (2 mg/ml), a well-established medication that has been used in medicine for over six decades. At low doses taken once weekly, Jylamvo is used as a disease-modifying antirheumatic drug (DMARD) for treating active rheumatoid arthritis in adults, severe recalcitrant psoriasis, and polyarthritic forms of severe juvenile idiopathic arthritis. At higher doses, methotrexate is also used as an antineoplastic agent in the treatment of certain cancers. The oral solution formulation offers precise dose adjustment and is particularly suitable for patients who have difficulty swallowing tablets. Jylamvo requires careful medical supervision, regular blood monitoring, and folic acid supplementation.
Quick Facts: Jylamvo
Key Takeaways
- Jylamvo (methotrexate oral solution) is a disease-modifying drug taken once weekly only for rheumatoid arthritis and psoriasis – never daily, as daily dosing can cause fatal toxicity including severe bone marrow suppression and liver failure.
- Methotrexate is listed on the WHO Model List of Essential Medicines and is recommended by EULAR and ACR as the first-line DMARD for rheumatoid arthritis due to its proven long-term efficacy, safety profile, and favorable cost-effectiveness.
- Regular blood monitoring (complete blood count and liver function tests) is mandatory throughout treatment to detect early signs of bone marrow suppression, liver toxicity, or kidney impairment.
- Folic acid supplementation (typically 5 mg once weekly on a different day from methotrexate) is strongly recommended to reduce side effects such as nausea, mouth ulcers, and abnormal liver enzymes without compromising therapeutic efficacy.
- Jylamvo is strictly contraindicated in pregnancy and breastfeeding – methotrexate is a known teratogen. Both women and men must use reliable contraception during treatment and for at least 6 months (women) or 3 months (men) after stopping.
What Is Jylamvo and What Is It Used For?
Jylamvo contains the active substance methotrexate, a folate antagonist that was first synthesized in the 1940s and introduced into clinical practice in 1948 for the treatment of childhood leukemia. Over the following decades, methotrexate became one of the most versatile and widely used medications in medicine, with applications spanning oncology, rheumatology, dermatology, and transplant medicine. Today, methotrexate is included on the World Health Organization (WHO) Model List of Essential Medicines, underscoring its global importance in healthcare.
Methotrexate belongs to the class of drugs known as antimetabolites. Structurally, it is an analogue of folic acid (vitamin B9) and works by competitively inhibiting the enzyme dihydrofolate reductase (DHFR). This enzyme is critical for the synthesis of tetrahydrofolate, a cofactor required for the production of thymidylate, purine nucleotides, and the amino acids serine and methionine – all of which are essential building blocks for DNA and RNA synthesis. By blocking this metabolic pathway, methotrexate inhibits cell division, particularly in rapidly proliferating cells.
However, the mechanism of action of methotrexate at the low doses used in rheumatological and dermatological conditions (typically 7.5–25 mg once weekly) is distinct from its high-dose oncological action. At low doses, methotrexate primarily exerts its therapeutic effects through anti-inflammatory and immunomodulatory mechanisms. It promotes the extracellular release of adenosine, a potent endogenous anti-inflammatory mediator that suppresses inflammation by activating specific adenosine receptors on immune cells. Low-dose methotrexate also inhibits the production of pro-inflammatory cytokines (including tumor necrosis factor-alpha, interleukin-1, and interleukin-6), reduces T-cell activation, and modulates the function of neutrophils, monocytes, and macrophages. These combined effects reduce joint inflammation and damage in rheumatoid arthritis and suppress the excessive skin cell proliferation seen in psoriasis.
Jylamvo is specifically formulated as an oral solution at a concentration of 2 mg/ml, providing precise and flexible dosing. This formulation is particularly advantageous for patients who require dose adjustments in small increments, for children and adolescents for whom weight-based dosing is essential, and for patients who have difficulty swallowing tablets. The oral solution comes with a dosing syringe that allows accurate measurement of the prescribed dose.
Approved Indications
Jylamvo is approved for the following indications:
- Active rheumatoid arthritis (RA) in adults: Methotrexate is the anchor drug in RA treatment and is recommended as the first-line DMARD by both EULAR (European Alliance of Associations for Rheumatology) and ACR (American College of Rheumatology) guidelines. It slows disease progression, reduces joint swelling and pain, prevents joint damage and disability, and improves functional outcomes. In clinical trials and long-term observational studies, methotrexate has demonstrated sustained efficacy, with approximately 30–40% of patients achieving a meaningful clinical response (ACR50) and many maintaining benefit for years.
- Severe forms of psoriasis vulgaris: When psoriasis has not responded adequately to conventional therapies (including phototherapy, topical treatments, and other systemic agents), methotrexate provides effective systemic control of skin disease. It reduces the Psoriasis Area and Severity Index (PASI) score and improves quality of life. It is also effective for psoriatic arthritis.
- Polyarthritic forms of severe juvenile idiopathic arthritis (JIA): In children and adolescents from 3 years of age, methotrexate is the standard first-line DMARD when the disease does not respond adequately to non-steroidal anti-inflammatory drugs (NSAIDs). The efficacy of methotrexate in JIA has been confirmed in randomized controlled trials, with response rates of approximately 60–70%.
- Oncological indications: At higher doses, methotrexate is used for the maintenance treatment of acute lymphoblastic leukemia (ALL) and other neoplastic diseases as part of established chemotherapy protocols.
The oral solution formulation of Jylamvo offers several practical advantages over traditional methotrexate tablets: it allows for precise dose titration in small increments (important when adjusting to the optimal therapeutic dose), it is easier to swallow for children and patients with swallowing difficulties (dysphagia), and it provides more consistent absorption compared with some tablet formulations. The included dosing syringe ensures accurate dose measurement each time.
What Should You Know Before Taking Jylamvo?
Contraindications
Jylamvo must not be used in the following situations:
- Pregnancy and breastfeeding: Methotrexate is a known teratogen that causes severe birth defects (particularly craniofacial, limb, and central nervous system malformations) and fetal death. It is classified as FDA Pregnancy Category X. A negative pregnancy test is required before starting treatment. Methotrexate also passes into breast milk and is contraindicated during breastfeeding.
- Hypersensitivity: Known allergy to methotrexate or any of the excipients in Jylamvo.
- Significant hepatic impairment: Methotrexate is hepatotoxic and must not be used in patients with significant pre-existing liver disease, liver fibrosis, or cirrhosis.
- Severe renal impairment: Methotrexate is primarily excreted by the kidneys. Severe renal impairment (creatinine clearance below 20 ml/min) significantly increases the risk of methotrexate accumulation and toxicity.
- Pre-existing blood dyscrasias: Bone marrow suppression (leukopenia, thrombocytopenia, anemia) is a major risk of methotrexate therapy. Patients with pre-existing significant blood disorders should not use this medication.
- Active serious infections: Methotrexate suppresses immune function and must not be started during active serious infections, including tuberculosis, HIV, or severe fungal infections.
- Immunodeficiency syndromes: Methotrexate is contraindicated in patients with clinically significant immunodeficiency.
- Alcohol abuse: Concurrent alcohol use with methotrexate significantly increases the risk of hepatotoxicity, including fibrosis and cirrhosis.
- Mouth ulcers, active gastrointestinal ulcer disease: Methotrexate may worsen these conditions.
For rheumatological and dermatological conditions, Jylamvo must be taken only once a week, not daily. Accidental daily dosing of methotrexate has resulted in fatal outcomes due to severe bone marrow suppression (pancytopenia), overwhelming sepsis, and multi-organ failure. Always confirm with your doctor on which specific day of the week you should take your dose. Many prescribers recommend choosing a memorable day (e.g., “Methotrexate Monday”) to help prevent dosing errors.
Warnings and Precautions
Before and during treatment with Jylamvo, the following precautions are essential:
- Blood monitoring: Complete blood counts (including differential white cell count and platelet count) and liver function tests must be performed before starting treatment, weekly during the first month, every two weeks during the second and third months, and at least monthly thereafter. Any significant decline in blood counts requires dose reduction or temporary discontinuation.
- Liver monitoring: Liver function tests (ALT, AST, albumin, bilirubin) should be monitored regularly. Persistent elevation of liver enzymes may require dose reduction or discontinuation. Liver biopsy may be considered in selected cases, particularly if long-term treatment is planned.
- Kidney function: Serum creatinine and urea should be monitored regularly, as methotrexate is primarily renally excreted. Dehydration can significantly increase methotrexate toxicity.
- Lung toxicity: Methotrexate can cause interstitial pneumonitis, a potentially serious and occasionally fatal complication. Patients who develop new or worsening cough, dyspnea (shortness of breath), or fever should stop methotrexate and seek immediate medical evaluation. A baseline chest X-ray is recommended before starting treatment.
- Infections: Methotrexate suppresses immune function and increases susceptibility to infections, including opportunistic infections. Live vaccines should be avoided during treatment. Patients should be screened for latent tuberculosis and hepatitis B/C before starting therapy.
- Skin reactions: Severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported rarely. Sun exposure should be avoided or minimized as methotrexate can cause photosensitivity.
- Lymphoproliferative disorders: Cases of lymphoma and other lymphoproliferative disorders have been reported in patients receiving low-dose methotrexate, some of which regressed upon discontinuation of the drug.
- Folic acid supplementation: Folic acid 5 mg once weekly (on a different day from methotrexate) is strongly recommended by EULAR, ACR, and BAD guidelines to reduce gastrointestinal side effects, mouth ulcers, and liver enzyme elevations.
Pregnancy and Breastfeeding
Methotrexate is strictly contraindicated during pregnancy. It is classified as a teratogen and an abortifacient. Exposure during the first trimester is associated with the “methotrexate embryopathy” syndrome, which includes craniofacial abnormalities (skull ossification defects, broad nasal bridge, shallow orbits), limb defects, and central nervous system malformations. The risk of spontaneous miscarriage is also significantly increased.
Women of childbearing potential must have a negative pregnancy test documented before starting Jylamvo. They must use highly effective contraception (with a failure rate of less than 1% per year) during treatment and for at least 6 months after the last dose. If pregnancy occurs during methotrexate treatment, the drug must be stopped immediately and the patient should be referred for specialist counseling regarding the risk to the fetus.
Men taking methotrexate should also use effective contraception during treatment and for at least 3 months after the last dose, as methotrexate may affect spermatogenesis (sperm production) and has the potential to cause genetic damage. Men should not donate sperm during treatment or for 3 months after discontinuation.
Methotrexate is excreted in breast milk in concentrations that could be harmful to the infant. Breastfeeding is therefore contraindicated during Jylamvo therapy and for at least one week after the last dose.
Fertility
Methotrexate can affect fertility in both women and men. In women, methotrexate may cause menstrual irregularities and, in some cases, reversible infertility through effects on oogenesis. In men, methotrexate can cause oligospermia (reduced sperm count), which is generally reversible after discontinuation. Patients of reproductive age should discuss fertility preservation options with their doctor before starting treatment, particularly if long-term therapy is anticipated.
How Does Jylamvo Interact with Other Drugs?
Methotrexate has numerous clinically important drug interactions that can significantly affect its safety and efficacy. Unlike monoclonal antibodies, which generally have few drug interactions, methotrexate is a small molecule that undergoes active renal tubular secretion, is partially protein-bound, and its metabolism is influenced by concurrent medications. Understanding these interactions is critical to preventing potentially life-threatening toxicity.
The most important drug interactions with Jylamvo are categorized by severity below:
Major Interactions
| Drug / Class | Mechanism | Clinical Effect | Action Required |
|---|---|---|---|
| NSAIDs (ibuprofen, naproxen, diclofenac) | Reduce renal clearance of methotrexate; displace from protein binding | Increased methotrexate levels; risk of bone marrow suppression and mucosal toxicity | Avoid high-dose NSAIDs; use with caution at low doses under close monitoring |
| Trimethoprim / Sulfamethoxazole | Additive antifolate effect; reduces renal excretion of methotrexate | Potentially fatal pancytopenia (bone marrow failure) | Avoid combination; use alternative antibiotics |
| Penicillins (amoxicillin, piperacillin) | Reduce renal tubular secretion of methotrexate | Increased methotrexate levels and toxicity | Monitor methotrexate levels and blood counts; consider alternative antibiotics |
| Leflunomide | Additive hepatotoxic and myelosuppressive effects | Increased risk of pancytopenia and liver toxicity | Combination requires close monitoring; used in specialist settings only |
| Live vaccines | Immunosuppression from methotrexate | Risk of disseminated infection from live vaccine organisms | Contraindicated; use inactivated vaccines instead |
Moderate Interactions
| Drug / Class | Mechanism | Clinical Effect | Action Required |
|---|---|---|---|
| Proton pump inhibitors (omeprazole, lansoprazole) | May reduce renal clearance of methotrexate via inhibition of breast cancer resistance protein (BCRP) | Increased methotrexate levels, especially at high doses | Monitor; consider H2-receptor antagonists as alternatives |
| Phenytoin | Methotrexate may increase phenytoin levels by displacing from protein binding | Phenytoin toxicity (nystagmus, ataxia, confusion) | Monitor phenytoin levels |
| Theophylline | Methotrexate may reduce theophylline clearance | Increased theophylline levels and toxicity risk | Monitor theophylline levels |
| Hepatotoxic drugs | Additive liver toxicity | Increased risk of liver damage | Avoid or monitor liver function closely; minimize alcohol |
| Nephrotoxic drugs (e.g., ciclosporin, aminoglycosides) | Reduced renal function impairs methotrexate clearance | Methotrexate accumulation and toxicity | Monitor kidney function and methotrexate levels |
Alcohol consumption should be avoided or strictly limited during Jylamvo therapy. Both methotrexate and alcohol are hepatotoxic, and their combination significantly increases the risk of liver fibrosis and cirrhosis. Most guidelines recommend either complete abstinence or limiting intake to no more than 2 units per week.
Always tell your doctor, pharmacist, or nurse about all medications you are currently taking, including prescription medicines, over-the-counter drugs, herbal supplements, and vitamins. Even common over-the-counter painkillers (such as ibuprofen) can significantly interact with methotrexate. Do not start any new medication without consulting your prescriber.
What Is the Correct Dosage of Jylamvo?
Jylamvo should always be used exactly as your doctor has prescribed. The dosage depends on the condition being treated, your body weight, kidney function, and response to treatment. The oral solution is supplied with a graduated dosing syringe for accurate measurement. It is critical to remember that for rheumatological and dermatological indications, Jylamvo is taken once per week only – not once daily.
Adults – Rheumatoid Arthritis
Rheumatoid Arthritis Dosing
The recommended starting dose is 7.5 mg once weekly, taken as a single dose or divided into three doses of 2.5 mg given at 12-hour intervals over a 24-hour period. The dose may be gradually increased by 2.5 mg every 2–4 weeks, depending on clinical response and tolerability, up to a maximum of 25 mg per week. A clinical response is usually expected within 4–8 weeks. If no meaningful improvement is seen after 6–8 weeks at an adequate dose, treatment should be reassessed.
Adults – Psoriasis
Psoriasis Dosing
A test dose of 2.5–5 mg is recommended one week before starting regular treatment to assess individual tolerance. If blood counts remain normal after one week, the usual starting dose is 7.5 mg once weekly, which may be increased gradually by 2.5 mg per week up to a maximum of 25 mg per week. Once optimal response is achieved, the dose should be reduced to the lowest effective maintenance dose.
Children – Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis Dosing (from 3 years)
The recommended dose is 10–15 mg/m² body surface area once weekly. In treatment-refractory cases, the dose may be increased to 20 mg/m² per week. However, higher doses require more frequent monitoring. The oral solution formulation of Jylamvo is particularly suitable for children, as it allows precise weight-based dose adjustment.
Dosing in Oncology
Oncological Dosing
For acute lymphoblastic leukemia (ALL) maintenance therapy, the usual dose is 15–20 mg/m² body surface area once or twice weekly, as part of established combination chemotherapy protocols. Oncological dosing is determined by the treating oncologist based on the specific protocol, patient response, and tolerance. High-dose methotrexate protocols (exceeding 100 mg/m²) require leucovorin rescue and are administered only in specialized oncology units.
Elderly Patients
Elderly patients may require dose reduction due to age-related decreases in kidney and liver function, reduced folate stores, and increased susceptibility to side effects. A lower starting dose (e.g., 5–7.5 mg per week) is often appropriate, with gradual dose increases under close monitoring of blood counts, liver function, and renal function.
Patients with Renal Impairment
| Creatinine Clearance | Dose Adjustment |
|---|---|
| > 50 ml/min | No adjustment required |
| 30–50 ml/min | Reduce dose by 50%; monitor closely |
| < 30 ml/min | Contraindicated – do not use |
Missed Dose
If you forget to take your weekly dose of Jylamvo, take it as soon as you remember, provided it is within 2 days of the scheduled dose. Do not take a double dose to make up for a missed dose. If more than 2 days have passed, skip the missed dose and take the next dose on the usual day. Contact your doctor if you are unsure about what to do. Using a weekly medication organizer, a phone alarm, or a calendar reminder on the same day each week can help prevent missed doses.
Overdose
Methotrexate overdose can be life-threatening. Symptoms of overdose include severe nausea, vomiting, oral ulceration, gastrointestinal bleeding, bone marrow suppression (which may manifest as easy bruising, unusual bleeding, fever, or signs of infection), renal failure, and hepatic toxicity. If overdose is suspected or if methotrexate has been taken daily instead of weekly, seek emergency medical attention immediately. The specific antidote for methotrexate toxicity is folinic acid (leucovorin), also known as calcium folinate. Folinic acid rescue should be initiated as soon as possible after overdose, preferably within 24 hours, as its efficacy diminishes with time. In severe cases, high-flux hemodialysis or glucarpidase (an enzyme that rapidly degrades methotrexate) may be required.
How to Use the Oral Solution
Jylamvo oral solution should be measured using the dosing syringe provided with the package. Follow these steps:
- Preparation: Open the bottle and insert the syringe adapter into the bottle neck if not already fitted. Invert the bottle with the syringe inserted.
- Measuring: Pull the syringe plunger slowly to the prescribed dose marking. If air bubbles appear, push the solution back into the bottle and draw up the dose again.
- Administration: Slowly squirt the solution into the inner cheek of the mouth. Do not squirt it directly to the back of the throat to avoid choking.
- After use: Close the bottle. Wash the syringe with clean water after each use. Keep the adapter in the bottle.
Jylamvo can be taken with or without food. However, if nausea is a problem, taking it with a light meal or at bedtime may help reduce gastrointestinal discomfort.
What Are the Side Effects of Jylamvo?
Like all medicines, Jylamvo can cause side effects, although not everyone will experience them. The side effect profile of methotrexate is well characterized from decades of clinical use and extensive post-marketing surveillance. Many of the common side effects can be significantly reduced with folic acid supplementation, dose adjustment, and appropriate monitoring. Understanding the potential side effects helps patients recognize early warning signs and seek timely medical advice.
The overall tolerability of low-dose methotrexate is generally good, and most patients are able to continue treatment long-term. In clinical studies and large observational registries, approximately 10–30% of patients discontinue methotrexate due to adverse effects, with gastrointestinal intolerance and liver enzyme elevations being the most common reasons. Serious adverse effects (such as severe bone marrow suppression, pneumonitis, or significant hepatotoxicity) occur in a small minority of patients and are usually detected through routine monitoring.
Very Common
May affect more than 1 in 10 people
- Nausea and loss of appetite
- Abdominal pain
- Stomatitis (inflammation and ulcers in the mouth)
- Elevated liver transaminases (ALT, AST)
Common
May affect up to 1 in 10 people
- Diarrhea
- Fatigue and malaise
- Headache and dizziness
- Leukopenia (low white blood cell count)
- Thrombocytopenia (low platelet count)
- Anemia
- Rash and itching
- Alopecia (hair thinning or hair loss)
- Increased susceptibility to infections
Uncommon
May affect up to 1 in 100 people
- Interstitial pneumonitis (lung inflammation) – potentially serious
- Liver fibrosis and fatty liver changes
- Herpes zoster (shingles) reactivation
- Photosensitivity (increased sensitivity to sunlight)
- Opportunistic infections
- Pancytopenia (suppression of all blood cell types)
- Vomiting
- Gingivitis (gum inflammation)
Rare
May affect up to 1 in 1,000 people
- Liver cirrhosis
- Severe bone marrow failure (agranulocytosis, aplastic anemia)
- Lymphoproliferative disorders (lymphoma)
- Stevens-Johnson syndrome and toxic epidermal necrolysis
- Pulmonary fibrosis
- Renal failure
- Severe infections (sepsis)
- Anaphylactoid reactions
Not Known
Frequency cannot be estimated from available data
- Neurotoxicity (cognitive impairment, leukoencephalopathy) – primarily at high doses
- Osteonecrosis of the jaw
- Progressive multifocal leukoencephalopathy (PML) in immunosuppressed patients
Gastrointestinal side effects (nausea, loss of appetite, abdominal pain, and mouth ulcers) are the most commonly reported adverse effects of methotrexate. These symptoms often improve with folic acid supplementation, dose splitting (taking the weekly dose as three divided doses over 24 hours), or taking methotrexate at bedtime. Some patients experience “methotrexate intolerance,” a conditioned nausea response where anticipation of taking the medication triggers nausea even before the dose is taken. Antiemetic medications may be helpful in such cases.
Liver toxicity is a well-recognized concern with long-term methotrexate use. Transient elevations of liver transaminases are common and often clinically insignificant, but persistent or marked elevations require dose reduction or discontinuation. The risk of progressive liver fibrosis and cirrhosis is increased by concurrent alcohol consumption, obesity, diabetes mellitus, and pre-existing liver disease. Cumulative dose is also a factor, though the risk of significant liver fibrosis with modern monitoring protocols is low.
Pulmonary toxicity (interstitial pneumonitis) is an uncommon but potentially serious complication that can occur at any time during treatment and is not dose-dependent. Symptoms include progressive dry cough, shortness of breath, fever, and general malaise. If pulmonary toxicity is suspected, methotrexate should be stopped immediately and the patient should be evaluated urgently. Treatment typically involves corticosteroids.
Bone marrow suppression is the most serious acute toxicity of methotrexate. Risk factors include renal impairment (which reduces methotrexate clearance), drug interactions (particularly with NSAIDs and trimethoprim/sulfamethoxazole), low folate status, and advanced age. Early detection through regular blood monitoring is essential.
Contact your doctor immediately or go to the emergency department if you experience: unexplained bruising or bleeding, persistent sore throat or fever, severe mouth ulcers, persistent dry cough or difficulty breathing, dark urine or yellowing of the skin/eyes, severe skin rash, or signs of infection. These may indicate serious complications requiring urgent medical evaluation.
How Should You Store Jylamvo?
Proper storage of Jylamvo is important to maintain the quality, safety, and efficacy of the medication. Methotrexate is a cytotoxic substance, and special precautions should be observed when handling the oral solution.
- Temperature: Store below 25°C (77°F) at all times. Do not refrigerate or freeze the oral solution.
- Light protection: Keep the bottle in the outer carton to protect the solution from light, as methotrexate may degrade when exposed to light.
- Shelf life after opening: Once the bottle is first opened, Jylamvo oral solution should be used within 3 months. Write the date of opening on the bottle or carton. Discard any remaining solution after 3 months, even if the bottle is not empty.
- Keep out of reach of children: Methotrexate is a potent cytotoxic medication. Store the bottle in a secure location where children cannot access it.
- Expiry date: Do not use Jylamvo after the expiry date stated on the label and carton after “EXP.”
- Handling precautions: Methotrexate is classified as a cytotoxic agent. If the oral solution is spilled on the skin, wash the affected area immediately with soap and water. If it contacts the eyes, rinse thoroughly with water and seek medical advice. Pregnant women or women who may become pregnant should avoid handling Jylamvo if possible. Caregivers should wash their hands after administering the medication and after handling the bottle or dosing syringe.
- Disposal: Do not dispose of Jylamvo via household waste or wastewater. Return any unused medication to your pharmacist for safe disposal, as methotrexate is an environmental hazard.
What Does Jylamvo Contain?
Active Ingredient
The active substance is methotrexate. Each milliliter of oral solution contains 2 mg of methotrexate. Methotrexate is a folate analogue with the molecular formula C20H22N8O5 and a molecular weight of 454.44 g/mol. It is a yellow-orange crystalline powder that is practically insoluble in water in its acid form but dissolves readily in dilute solutions of alkali hydroxides and carbonates.
Inactive Ingredients (Excipients)
| Ingredient | Role | Notes |
|---|---|---|
| Methotrexate | Active substance (antimetabolite / DMARD) | 2 mg per ml |
| Macrogol 400 | Solubilizer / co-solvent | Helps dissolve the active substance |
| Glycerol | Humectant / sweetener | Improves palatability and texture |
| Methyl parahydroxybenzoate (E218) | Preservative | May cause allergic reactions (possibly delayed) |
| Ethyl parahydroxybenzoate (E214) | Preservative | May cause allergic reactions (possibly delayed) |
| Orange flavoring | Flavoring agent | Improves taste; contains maltodextrin |
| Sucralose | Sweetener | Non-caloric sweetener |
| Purified water | Vehicle / solvent | Base of the solution |
Jylamvo oral solution is a clear, yellow to brown-colored solution with a characteristic orange flavor. Each bottle contains 60 ml of solution, which corresponds to 120 mg of methotrexate. The solution is supplied in an amber glass bottle with a child-resistant cap and includes an oral dosing syringe and a push-in bottle adapter for accurate dose measurement.
Jylamvo contains methyl parahydroxybenzoate (E218) and ethyl parahydroxybenzoate (E214), which belong to the paraben family and may cause allergic reactions in some individuals (possibly delayed). If you have known sensitivity to parabens, inform your doctor before starting Jylamvo. The product does not contain gluten, lactose, or tartrazine.
Frequently Asked Questions About Jylamvo
Jylamvo contains the same active ingredient (methotrexate) as methotrexate tablets, but in an oral solution form at a concentration of 2 mg/ml. The key advantages of the liquid formulation include more precise dose adjustment (important for dose titration and for children requiring weight-based dosing), easier swallowing for patients with dysphagia, and potentially more consistent absorption. The indications, mechanism of action, and side effect profile are the same as for methotrexate tablets.
For rheumatoid arthritis, the full therapeutic effect of methotrexate typically takes 4 to 8 weeks to become apparent, though some patients may notice improvement within 3–4 weeks. Maximum benefit may not be achieved until 3–6 months of treatment. For psoriasis, improvement is usually seen within 2–6 weeks. It is important to continue taking Jylamvo as prescribed even if you do not feel immediate improvement, as the anti-inflammatory and disease-modifying effects build up over time. If no meaningful improvement is seen after 6–8 weeks at an adequate dose, your doctor may adjust the dose or consider alternative treatments.
You should discuss any painkiller use with your doctor. Paracetamol (acetaminophen) is generally considered the safest option for pain relief during methotrexate treatment, although it should be used at the lowest effective dose. NSAIDs (such as ibuprofen, naproxen, and diclofenac) should be used with caution, as they can reduce methotrexate clearance and increase toxicity. Low-dose aspirin for cardiovascular prevention is generally acceptable but should be discussed with your doctor. Avoid co-codamol or other combination products without checking with your pharmacist or prescriber.
Live vaccines (such as MMR, varicella, yellow fever, live influenza nasal spray, and BCG) are contraindicated during methotrexate treatment due to the risk of disseminated infection from the weakened live organisms. Inactivated vaccines (such as the flu injection, COVID-19 vaccines, pneumococcal vaccine, and hepatitis B vaccine) are safe and recommended, though the immune response may be somewhat reduced. Your doctor may recommend pausing methotrexate temporarily (usually for 2 weeks after certain vaccinations) to improve immune response, particularly for annual flu and COVID-19 vaccinations.
If you have accidentally taken Jylamvo daily instead of weekly, stop taking it immediately and seek urgent medical attention. Daily dosing of methotrexate at rheumatological/dermatological doses can cause potentially fatal toxicity, including severe bone marrow suppression (which may not manifest for 7–14 days), liver failure, and overwhelming sepsis. You should go to the nearest emergency department, taking the Jylamvo bottle with you. Treatment of methotrexate overdose involves folinic acid (leucovorin) rescue, supportive care, and intensive monitoring. Early intervention significantly improves outcomes.
Yes, you can travel with Jylamvo. Keep the medication in its original packaging with the prescription label visible. Store it below 25°C and protect from light. Carry it in your hand luggage when flying (to avoid temperature extremes in the cargo hold). It is advisable to carry a letter from your doctor confirming that you require the medication, particularly when traveling internationally. Ensure you have enough medication for the entire trip, plus extra in case of travel delays. Remember that blood monitoring may need to be arranged in advance at your destination if you will be away for an extended period.
References
- European Medicines Agency (EMA). Jylamvo – Summary of Product Characteristics. Available at: www.ema.europa.eu. Last updated 2025.
- Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
- Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res. 2021;73(7):924–939.
- Smith CH, Yiu ZZN, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020. Br J Dermatol. 2020;183(4):628–637.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List (2023). Geneva: WHO; 2023.
- Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis. 2009;68(7):1094–1099.
- Shea B, Swinden MV, Tanjong Ghogomu E, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. 2013;(5):CD000951.
- Conway R, Low C, Coughlan RJ, O’Donnell MJ, Carey JJ. Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheumatol. 2014;66(4):803–812.
- British National Formulary (BNF). Methotrexate. Available at: bnf.nice.org.uk. Accessed January 2026.
- Hazlewood GS, Barnabe C, Tomlinson G, et al. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis. BMJ. 2016;353:i1777.
About Our Medical Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising board-certified specialists in rheumatology, dermatology, oncology, and clinical pharmacology. All medical information is evidence-based and reviewed according to international guidelines from the EULAR, ACR, EMA, FDA, and WHO.
Our editorial process follows the GRADE evidence framework, ensuring that all recommendations are graded according to the quality of supporting evidence. We maintain strict editorial independence with no commercial funding or pharmaceutical sponsorship. For more information about our team and editorial standards, visit our Medical Team and Editorial Standards pages.